Synchron, formerly SmartStent Pty, is a brain interface platform company that is leading the field of implantable neural interface technology.

Synchron is developing bloodstream-enabled solutions for previously-untreatable nervous system conditions.

Synchron was founded in Melbourne in 2016 by Nicholas Opie. The company is headquartered in Brooklyn, NY, with offices in Silicon Valley, CA and R&D facilities in Melbourne, Australia.

Synchron has been developing a BCI platform that avoids the need for open brain surgery by using a minimally-invasive procedure. Synchron's Stentrode is the world’s first motor neuroprosthesis and is implanted within the motor cortex of the brain via the jugular vein in an endovascular procedure.

Synchron’s first platform product (Synchron Switch™ BCI) is is designed to detect and wirelessly transmit motor intent out of the brain, restoring a capability for severely paralyzed patients to control personal devices with hands-free point-and-click.

Synchron has 60 patent applications in the interventional neuro electrophysiology space spanning conditions including paralysis, epilepsy, depression, Parkinson’s disease, pain, addiction and non-medical applications.

Synchron is backed by ARCH Venture Partners, Khosla Ventures, Forepont Capital Partners, Gates Frontier, Bezos Expeditions, Reliance Digital Health Limited, Greenoaks, Alumni Ventures, Moore Strategic Ventures, Neurotechnology Investors (NTI), ID8 Investments, Shanda Group, General Advance, Subversive Capital, and others. The company raised $75M in Series C round on Dec 15, 2022. This brings Synchron's total funding to $134M to date.